CH 275

Research use only, not for human use.

Potent somatostatin receptor 1 (sst1) agonist; displays selectivity for sst1 (IC50 values are 30.9 nM, 345 nM, > 1 μM, > 10 μM and > 10μM for human sst1, sst3, sst4, sst2 and sst5 respectively). Attenuates somatostatin release in the rat nucleus accumbens.

Potent somatostatin receptor 1 (sst1) agonist; displays selectivity for sst1 (IC50 values are 30.9 nM, 345 nM, > 1 μM, > 10 μM and > 10μM for human sst1, sst3, sst4, sst2 and sst5 respectively). Attenuates somatostatin release in the rat nucleus accumbens.

CH275 (100 nM) activates neprilysin activity, wheras treatment with cyclo-SRIF can complete this activation in vitro in primary neuron-based cell culture system, a mixture of wildtype hippocampal, cortical and striatal neuron.

CH275 (osmotic pump administration; 56 μM; two weeks) decreases the?level of neprilysin/SRIF in the?App?knock-in mice.CH275 directly injects into the Lacunosum molecular layer (Lmol) layer of 2-month-old AppNL-G-F mice for four months. AppNL-G-F mice begin to exhibit Aβ plaques at two months of age, but CH275 leads to robustly increased the expression of neprilysin in hippocampus which is paralleled by a clear reduction in Aβ plaque load in the same region, and without causing any toxic side effects.

——

GPCR/G Protein

Somatostatin Receptor

——

——

——

174688-78-9

1485.8

C74H96N14O15S2

>98% (HPLC)

water:0.30 mg/mL

[H]N[C@H]1CSSC[C@H](NC[C@H](CO)NC(=O)[C@H](NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](NC(=O)[C@@H](CC2=CC=C(CNC(C)C)C=C2)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCCCN)NC1=O)[C@@H](C)O)[C@@H](C)O)C(O)=O

——

(-20℃)

With Ice Pack

≥ 2 years